Cocarcinogenicity of foundry silica sand in hamsters.
Authors
Niemeier RW; Mulligan LT; Rowland J
Source
Silica, silicosis, and cancer: controversy in occupational medicine. Goldsmith DF, Winn DM, Shy CM, eds. New York: Praeger, 1986 Jan; :215-227
Link
NIOSHTIC No.
00171383
Abstract
The cocarcinogenicity of foundry silica sand was investigated in hamsters. Respirable size particulates, obtained from commercial samples of foundry silica sand, ferric-oxide (1309371), and Min-U- Sil (14808607), a reference quartz, were administered in saline by intratracheal instillation to groups of 50 male Syrian-golden- hamsters. Hamsters received 15 weekly administrations of either particulate alone or particulate plus 3 milligrams benzo(a)pyrene (50328) (BaP). The hamsters were killed when moribund or at 92 weeks after the first treatment, and tissue were examined for histopathologic changes. The principal treatment effects were respiratory tract tumors, which were observed in every group receiving the BaP. Tumor incidences in the silica sand/BaP and Min- U-Sil/BaP groups were significantly greater than that in the saline/BaP group but did not differ from that in the ferric- oxide/BaP positive control group. Mean percent of lung tumor bearing animals ranged from 47 for the saline/BaP group to 90 for the Min-U-Sil/BaP group. Mean latency ranged from 67 to 70 weeks for the ferric-oxide/BaP, silica sand/BaP, and Min-U-Sil/BaP groups to 73 weeks for the saline/BaP group. Squamous cell carcinomas, adenosquamous carcinomas, and adenocarcinomas of the lungs and bronchi were the tumor types most commonly found. The saline control group had no respiratory tumors. Of the groups given particulates without BaP, only the ferric-oxide (incidence, 1/41) and Min-U-Sil (incidence, 1/50) groups developed respiratory tract tumors. Pulmonary fibrosis was not observed, but granulomatous inflammation occurred at a significantly increased rate in groups given silica sand or Min-U-Sil.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.